In a comparison study, subcutaneous mirikizumab proved superior to subcutaneous in achieving skin clearance in patients with plaque psoriasis…... [Read More]
Study Finds Mirikizumab Superior to Secukinumab for Plaque Psoriasis
Search results for: psoriasis
Study Finds Increased Risk of Cancer in Psoriasis Patients
Recent research reinforces the finding that psoriasis patients have a slightly increased risk of cancer, specifically keratinocyte cancer and lymphomas. However, the study found no association between cancer and the use of biologic treatments in this patient population…... [Read More]
Study Compares Ixekizumab with Ustekinumab for the Treatment of Nail Psoriasis
In a head-to-head study, ixekizumab was a more effective treatment for nail psoriasis than ustekinumab and resulted in greater skin clearance for patients with plaque psoriasis…... [Read More]
Ixekizumab May Improve Pain & Sexual Health in Patients with Genital Psoriasis
Research has shown ixekizumab improves pain and the sexual health of patients with genital psoriasis…... [Read More]
Apremilast Promising for Plaque Psoriasis
Apremilast has been shown to improve the signs and symptoms of mild to moderate plaque psoriasis in adults, according to new research…... [Read More]
Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis
In a phase 3, comparator study in adults with plaque psoriasis, patients taking
risankizumab achieved greater skin clearance than those taking secukinumab…... [Read More]
Tildrakizumab Promising for Psoriasis in Patients with PsA
New research shows tildrakizumab may significantly improve psoriasis in patients with active psoriatic arthritis…... [Read More]
Rheumatology Drugs at a Glance, Part 2: Psoriasis
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to… [Read More]
IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis
In a second response letter, the FDA has cited the onset and duration of intravenous meloxicam, a non-opioid pain treatment, as concerns that it fails to meet prescriber expectations…... [Read More]
Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis
Japan has approved risankizumab for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults…... [Read More]
- 1
- 2
- 3
- …
- 42
- Next Page »